Use of Ritlecitinib for the Treatment of Alopecia Areata

    December 2023 in “ Journal of Ayub Medical College Abbottabad ”
    Fatima Zahoor, Muhammad Waleed Tahir
    Image of study
    TLDR Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
    Ritlecitinib, a JAK3 and TEC inhibitor, has been approved by the FDA for treating alopecia areata, an autoimmune condition causing hair loss. Unlike Baricitinib, Ritlecitinib is safe for patients aged 12 and older, making it a significant option for younger individuals. The ALLEGRO Phase 2b/3 trial demonstrated that 50 mg of Ritlecitinib daily for 24 weeks resulted in 80% or more scalp hair coverage in treated patients compared to a placebo. Common side effects include headache, respiratory infections, and gastrointestinal issues. Ritlecitinib offers a less invasive treatment with fewer side effects compared to other therapies.
    Discuss this study in the Community →

    Related Community Posts Join

    2 / 2 results
      [object Object]

      community How do we only have two treatments to combat hair loss at this point in time?

      in Chat  211 upvotes 1 year ago
      The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.

    Related Research

    1 / 1 results